Latest updates
- In the press Exonate first-in-class eye drop Phase Ib/IIa trial data demonstrate safety and biological activity in treatment of diabetic retinopathy and diabetic macular oedema
- Insights Biotech Showcase, San Francisco 2024
- In the press Exonate announces successful completion of Phase Ib/IIa trial in diabetic macular oedema
- Insights Exonate at Biotrinity 2022
- Company news Exonate at Biotrinity 2021
- Insights Exonate announces involvement in exciting STEM outreach project.